Search the GHTC website

MMV is a leading product development partnership that works to reduce the burden of malaria in disease-endemic countries by discovering, developing, and delivering new, effective, and affordable antimalarial drugs. Myriam El Gaaloul is the MiMBa R&D Co-lead and a Director of Clinical Sciences at MMV. Maud Majeres Lugand is the MiMBa Access and Product Management Co-lead and an Associate Director of Social Research at MMV, and Doreen Akiyo Yomoah is a Communications Officer at MMV.

Blog posts written by Medicines for Malaria Venture

Total of 1 blog post

October 17, 2022

Developing new antimalarial drugs for malaria-free pregnancies

The 2022 World Health Summit, taking place from October 16 to 18, brings together scientific, political, private, and civil society sectors to discuss the achievement of health for all. It is an opportunity to draw attention to the fact that pregnant women are underserved by currently available antimalarial therapies. Medicines for Malaria Venture (MMV), through its Malaria in mothers and babies (MiMBa) strategy, is working with partners to close critical gaps in the availability of well-tolerated malaria prevention and treatment methods for pregnant women to achieve true health for all.